Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
'I carried my wife's body for an hour and a half' - BBC hears stories of protesters killed in Iran - 2‘And then we saw the little head.’ Scientists witness rare sperm whale birth
- 3Activist vessel collides with krill trawler in Antarctic confrontation
- 4Surge of off‑lease electric vehicles expected to drive down used EV prices
- 57 Extraordinary Efficiency Applications for Experts
- Washington state experiences historic flooding as Skagit River hits record high level. See flooding maps, highway closures and forecasts.
- 5 Eating routine Well disposed Snacks to Keep You Fulfilled
- Move. Cheer. Dance. Do the wave. How to tap into the collective joy of 'we mode'
- Only 30% of young people in Israel optimistic about future, Aluma survey reveals
- UN experts urge investigation into Israel’s killing of Lebanese journalists
- The Fate of Mechanical technology: 5 Headways Forming Tomorrow
- These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- UNICEF: More than 100 children killed in Gaza since ceasefire
